Trump announces AstraZeneca deal to lower U.S. drug prices

U.S. President Donald Trump at the White House in Washington, D.C., U.S., October 10, 2025
Reuters

President Donald Trump unveiled a new agreement with pharmaceutical company AstraZeneca on October 10, aiming to reduce prescription drug costs in the United States.

Under the deal, AstraZeneca will provide all its prescription medications to Medicaid at "most favored nations" prices, ensuring that U.S. patients pay no more than the lowest prices available globally. Additionally, the company will list its medications on the upcoming TrumpRx platform, offering direct-to-consumer discounts.

AstraZeneca CEO Pascal Soriot joined President Trump at the White House to announce the agreement. As part of the deal, AstraZeneca will also list its medications on the TrumpRx platform, a federal initiative launched in September 2025 to provide Americans with direct access to discounted prescription drugs. The platform is expected to launch in 2026 and aims to bypass traditional intermediaries to offer lower prices directly to consumers.

The AstraZeneca deal is expected to result in significant cost savings for American patients, particularly those covered by Medicaid. The agreement also includes provisions for AstraZeneca to invest $50 billion in U.S. manufacturing and research and development by 2030, including a $4.5 billion investment in a new facility in Virginia. This investment is anticipated to create thousands of jobs and strengthen the U.S. pharmaceutical manufacturing sector.

Tags